ADC

25개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved25 programs
ADCLimited DatastaleGilead SciencesPhase 2

LG (Labetuzumab Govitecan, Labetuzumab Govitecan (LG))

Metastatic Colorectal Cancer; Colon Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#ADC#Phase2#antibody-drug-conjugate#ColonCancer+1
Trials 1Status Discontinued
ADCLimited DatastaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Megestrol Acetate + Trastuzumab Deruxtecan)

Advanced/Metastatic Breast Cancer; HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer · HER2

#HER2#ADC#Phase3#antibody-drug-conjugate#Advanced+3
Trials 1Status Recruiting
ADCLimited DatastaleGileadPhase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan)

Metastatic Breast Cancer ( HER2 Negative) · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MetastaticBreastCancerHER2Negati+1
Trials 1Status Recruiting
ADCLimited DatastaleFudan UniversityPhase 2

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

Bladder Cancer; Metastatic Urothelial Carcinoma · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#MetastaticUrothelialCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleBiying ChenPhase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor)

Recurrent or Metastatic Head and Neck Carcinoma · MET

#MET#ADC#Phase2#antibody-drug-conjugate#RecurrentorMetastaticHeadandNeck+1
Trials 1Status Recruiting

2 / 2 pages

← PreviousNext →